PHGDH and liver cancer: Although cMyc controls many aspects of tumorigenesis, efforts to use cMyc as a therapeutic target has been frustrating, indicating some mysteries remain in our understanding of cMyc transactivation.[50, 51, 52] Our study suggests the potential utility of cMyc transactivation by disrupting the PHGDH/cMyc axis in liver cancer cells.